'Genetic profiling' and ovarian cancer therapy (Review)

Nadia Vella, Marco Aiello, Alessia Erika Russo, Aurora Scalisi, Demetrios A. Spandidos, Giuseppe Toffoli, Roberto Sorio, Massimo Libra, Franca Stivala

Research output: Contribution to journalArticle

Abstract

High variability observed among ovarian cancer patients in response to the same therapy and the related toxicity may be correlated to gene polymorphisms and genetic alterations affecting the metabolism of drugs commonly used to treat this tumor. Recent studies have shown a correlation between the polymorphisms characterizing GSTM1-T1 detoxifying enzymes and poor outcome in advanced ovarian cancer patients treated with platinum/paclitaxel-based chemotherapy. Multidrug resistance 1 (mdr-1) polymorphisms were found to be associated with resistance to paclitaxel treatment. Polymorphisms of MRP2, a protein involved in methotrexate, cisplatin and irinotecan active metabolite glucuronide transport, negatively affect platinum-based chemotherapy response. A similar occurrence has been observed with CYP1A1 Ile462Val and ercc1 C118T polymorphisms while patients who were carriers of MTHFR C677T polymorphism had a better response to methotrexate therapy, but an elevated risk of toxicity. Biological therapy with Bevacizumab, the anti-vascular endothelial growth factor has been shown to be less efficient in ovarian cancer patients carrying the polymorphism of the Interleukin-8 gene. Instead, polymorphisms in the XPD gene (Lys751Gln and Asp312Asn), a member of the nucleotide excision repair pathway, positively affects the response to therapy with carboplatin/paclitaxel. Therefore, the study of 'genetic profiling' is crucial to improving the clinician's ability to tailor effective therapy to the molecular profile of the patient while minimizing toxicities. This review describes clinical applications of the above genetic polymorphisms in ovarian cancer patients treated with platinum/paclitaxel-based chemotherapy.

Original languageEnglish
Pages (from-to)771-777
Number of pages7
JournalMolecular Medicine Reports
Volume4
Issue number5
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Polymorphism
Ovarian Neoplasms
Paclitaxel
Platinum
irinotecan
Chemotherapy
Methotrexate
Drug Therapy
Toxicity
Therapeutics
Genes
Biological Therapy
Cytochrome P-450 CYP1A1
Carboplatin
Glucuronides
Multiple Drug Resistance
Genetic Polymorphisms
Interleukin-8
DNA Repair
Vascular Endothelial Growth Factor A

Keywords

  • Biological therapy
  • Gene polymorphisms
  • Ovarian cancer

ASJC Scopus subject areas

  • Biochemistry
  • Cancer Research
  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Oncology

Cite this

Vella, N., Aiello, M., Russo, A. E., Scalisi, A., Spandidos, D. A., Toffoli, G., ... Stivala, F. (2011). 'Genetic profiling' and ovarian cancer therapy (Review). Molecular Medicine Reports, 4(5), 771-777. https://doi.org/10.3892/mmr.2011.512

'Genetic profiling' and ovarian cancer therapy (Review). / Vella, Nadia; Aiello, Marco; Russo, Alessia Erika; Scalisi, Aurora; Spandidos, Demetrios A.; Toffoli, Giuseppe; Sorio, Roberto; Libra, Massimo; Stivala, Franca.

In: Molecular Medicine Reports, Vol. 4, No. 5, 09.2011, p. 771-777.

Research output: Contribution to journalArticle

Vella, N, Aiello, M, Russo, AE, Scalisi, A, Spandidos, DA, Toffoli, G, Sorio, R, Libra, M & Stivala, F 2011, ''Genetic profiling' and ovarian cancer therapy (Review)', Molecular Medicine Reports, vol. 4, no. 5, pp. 771-777. https://doi.org/10.3892/mmr.2011.512
Vella N, Aiello M, Russo AE, Scalisi A, Spandidos DA, Toffoli G et al. 'Genetic profiling' and ovarian cancer therapy (Review). Molecular Medicine Reports. 2011 Sep;4(5):771-777. https://doi.org/10.3892/mmr.2011.512
Vella, Nadia ; Aiello, Marco ; Russo, Alessia Erika ; Scalisi, Aurora ; Spandidos, Demetrios A. ; Toffoli, Giuseppe ; Sorio, Roberto ; Libra, Massimo ; Stivala, Franca. / 'Genetic profiling' and ovarian cancer therapy (Review). In: Molecular Medicine Reports. 2011 ; Vol. 4, No. 5. pp. 771-777.
@article{b4349f59805d48b698a801f53e70fba3,
title = "'Genetic profiling' and ovarian cancer therapy (Review)",
abstract = "High variability observed among ovarian cancer patients in response to the same therapy and the related toxicity may be correlated to gene polymorphisms and genetic alterations affecting the metabolism of drugs commonly used to treat this tumor. Recent studies have shown a correlation between the polymorphisms characterizing GSTM1-T1 detoxifying enzymes and poor outcome in advanced ovarian cancer patients treated with platinum/paclitaxel-based chemotherapy. Multidrug resistance 1 (mdr-1) polymorphisms were found to be associated with resistance to paclitaxel treatment. Polymorphisms of MRP2, a protein involved in methotrexate, cisplatin and irinotecan active metabolite glucuronide transport, negatively affect platinum-based chemotherapy response. A similar occurrence has been observed with CYP1A1 Ile462Val and ercc1 C118T polymorphisms while patients who were carriers of MTHFR C677T polymorphism had a better response to methotrexate therapy, but an elevated risk of toxicity. Biological therapy with Bevacizumab, the anti-vascular endothelial growth factor has been shown to be less efficient in ovarian cancer patients carrying the polymorphism of the Interleukin-8 gene. Instead, polymorphisms in the XPD gene (Lys751Gln and Asp312Asn), a member of the nucleotide excision repair pathway, positively affects the response to therapy with carboplatin/paclitaxel. Therefore, the study of 'genetic profiling' is crucial to improving the clinician's ability to tailor effective therapy to the molecular profile of the patient while minimizing toxicities. This review describes clinical applications of the above genetic polymorphisms in ovarian cancer patients treated with platinum/paclitaxel-based chemotherapy.",
keywords = "Biological therapy, Gene polymorphisms, Ovarian cancer",
author = "Nadia Vella and Marco Aiello and Russo, {Alessia Erika} and Aurora Scalisi and Spandidos, {Demetrios A.} and Giuseppe Toffoli and Roberto Sorio and Massimo Libra and Franca Stivala",
year = "2011",
month = "9",
doi = "10.3892/mmr.2011.512",
language = "English",
volume = "4",
pages = "771--777",
journal = "Molecular Medicine Reports",
issn = "1791-2997",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - 'Genetic profiling' and ovarian cancer therapy (Review)

AU - Vella, Nadia

AU - Aiello, Marco

AU - Russo, Alessia Erika

AU - Scalisi, Aurora

AU - Spandidos, Demetrios A.

AU - Toffoli, Giuseppe

AU - Sorio, Roberto

AU - Libra, Massimo

AU - Stivala, Franca

PY - 2011/9

Y1 - 2011/9

N2 - High variability observed among ovarian cancer patients in response to the same therapy and the related toxicity may be correlated to gene polymorphisms and genetic alterations affecting the metabolism of drugs commonly used to treat this tumor. Recent studies have shown a correlation between the polymorphisms characterizing GSTM1-T1 detoxifying enzymes and poor outcome in advanced ovarian cancer patients treated with platinum/paclitaxel-based chemotherapy. Multidrug resistance 1 (mdr-1) polymorphisms were found to be associated with resistance to paclitaxel treatment. Polymorphisms of MRP2, a protein involved in methotrexate, cisplatin and irinotecan active metabolite glucuronide transport, negatively affect platinum-based chemotherapy response. A similar occurrence has been observed with CYP1A1 Ile462Val and ercc1 C118T polymorphisms while patients who were carriers of MTHFR C677T polymorphism had a better response to methotrexate therapy, but an elevated risk of toxicity. Biological therapy with Bevacizumab, the anti-vascular endothelial growth factor has been shown to be less efficient in ovarian cancer patients carrying the polymorphism of the Interleukin-8 gene. Instead, polymorphisms in the XPD gene (Lys751Gln and Asp312Asn), a member of the nucleotide excision repair pathway, positively affects the response to therapy with carboplatin/paclitaxel. Therefore, the study of 'genetic profiling' is crucial to improving the clinician's ability to tailor effective therapy to the molecular profile of the patient while minimizing toxicities. This review describes clinical applications of the above genetic polymorphisms in ovarian cancer patients treated with platinum/paclitaxel-based chemotherapy.

AB - High variability observed among ovarian cancer patients in response to the same therapy and the related toxicity may be correlated to gene polymorphisms and genetic alterations affecting the metabolism of drugs commonly used to treat this tumor. Recent studies have shown a correlation between the polymorphisms characterizing GSTM1-T1 detoxifying enzymes and poor outcome in advanced ovarian cancer patients treated with platinum/paclitaxel-based chemotherapy. Multidrug resistance 1 (mdr-1) polymorphisms were found to be associated with resistance to paclitaxel treatment. Polymorphisms of MRP2, a protein involved in methotrexate, cisplatin and irinotecan active metabolite glucuronide transport, negatively affect platinum-based chemotherapy response. A similar occurrence has been observed with CYP1A1 Ile462Val and ercc1 C118T polymorphisms while patients who were carriers of MTHFR C677T polymorphism had a better response to methotrexate therapy, but an elevated risk of toxicity. Biological therapy with Bevacizumab, the anti-vascular endothelial growth factor has been shown to be less efficient in ovarian cancer patients carrying the polymorphism of the Interleukin-8 gene. Instead, polymorphisms in the XPD gene (Lys751Gln and Asp312Asn), a member of the nucleotide excision repair pathway, positively affects the response to therapy with carboplatin/paclitaxel. Therefore, the study of 'genetic profiling' is crucial to improving the clinician's ability to tailor effective therapy to the molecular profile of the patient while minimizing toxicities. This review describes clinical applications of the above genetic polymorphisms in ovarian cancer patients treated with platinum/paclitaxel-based chemotherapy.

KW - Biological therapy

KW - Gene polymorphisms

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=79960393247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960393247&partnerID=8YFLogxK

U2 - 10.3892/mmr.2011.512

DO - 10.3892/mmr.2011.512

M3 - Article

C2 - 21687948

AN - SCOPUS:79960393247

VL - 4

SP - 771

EP - 777

JO - Molecular Medicine Reports

JF - Molecular Medicine Reports

SN - 1791-2997

IS - 5

ER -